/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Based in Foster City, California, Gilead Sciences, Inc. (GILD) is a global leader in biopharmaceuticals, renowned for its pioneering advancements in antiviral therapies. With a market cap of $91.32 billion, Gilead is recognized for its innovative portfolio that enhances patient care through cutting-edge treatments for diseases like HIV, hepatitis, and cancer. The company is set to announce its fiscal Q2 earnings results after the market closes on Thursday, Aug. 8.
Ahead of the event, analysts expect GILD to report a profit of $1.58 per share, up 17.9% from $1.34 per share in the year-ago quarter. In the last four quarters, the company surpassed Wall Street’s bottom-line estimates in two and missed on two occasions.